Advertising
Supported by
The company said its vaccine would restart in Britain while remaining suspended in the United States and other countries. Pfizer, a competitor, has announced an extension of its Array
By Carl Zimmer, Katie Thomas and Benjamin Mueller
Pharmaceutical company AstraZeneca said Saturday that it had resumed testing the coronavirus vaccine in Britain after postponing it six days ago for possible protection concerns, but that its tests in the United States and other countries were still pending.
The news came on the same day that a competitor, Pfizer, said he extended the trial of his coronavirus vaccine to another 44,000 people, a sharp increase in his previous target of 30,000, in an effort to recruit a more diverse organization of participants. and potentially reduce the time required to obtain the effects of the trial.
Together, progressions have raised new questions about when a vaccine could be obtained and have shown how unpredictable the progression of the vaccine can be, even when the world desperately expects anything that might end the pandemic.
The announcements of the two corporations lacked very important main points, which led to complaint that they were not open enough about the knowledge they collected. AstraZeneca did not provide data to assist in the resolution of partially resuming tests and gave no major points about a patient’s illness. That led to suspension. Pfizer did not know how he would find out the efficacy of the vaccine in his expanded trials.
Dr. Eric Topol, professor of molecular medicine at the Scripps Research Institute in San Diego and an expert in clinical trials, discovered that the two advertisements were disturbing, saying corporations were hiding information.
“The public has a right to know what’s going on,” he said. “The long term depends on it. “
AstraZeneca and Pfizer are among the 3 corporations that are currently testing their applicants in complex clinical trials in the United States (Modern is the third) in a record race to expand a coronavirus vaccine. All three said they hoped to have a vaccine in one position, at least for the highest-preceding teams – until the end of the year. On Saturday, Pfizer repeated previous statements that he might have an answer about the effectiveness of his vaccine until the end of October.
All three have also entered into multimillion-dollar agreements with the US government. Usa, either for your studies or to get a source of vaccines if they are safe and effective.
Advertising